It offers a non-invasive approach and has broad clinical relevance in cancer management. This comprehensive review primarily ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high ...

【导读】肝细胞癌（HCC）伴大血管浸润（MVI）的患者预后不佳，没有标准的围手术期治疗。该2期试验旨在研究围手术期替雷利珠单抗联合调强放疗（IMRT）治疗MVI可切除HCC的活性和安全性。2024年10月29日，海军军医大学附属东方肝胆外科医院王若愚 ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

前言一年一度的肿瘤领域盛会——2024年欧洲肿瘤内科学会亚洲年会（ESMO ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...